24/7 Market News Snapshot 07 July, 2025 – Mustang Bio, Inc. (NASDAQ:MBIO)

July 7, 2025

DENVER, Colo., 07 July, 2025 (www.247marketnews.com) – (NASDAQ:MBIO) are discussed in this article.
In an exciting development for Mustang Bio, Inc. (MBIO), shares surged significantly to $2.249 in pre-market trading, representing an impressive 89% increase from the previous close of $1.190. The robust trading volume of approximately 20.71 million shares indicates heightened investor interest, which may be encouraged by positive advancements within the company. This surge in market activity suggests a bullish outlook for Mustang Bio, as stakeholders await further updates that could enhance the company’s strategic position.

Concurrently, Mustang Bio has achieved a noteworthy milestone, garnering Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for MB-101, an IL13Ra2-targeted CAR T-cell therapy aimed at treating recurrent diffuse and anaplastic astrocytoma, along with glioblastoma (GBM). This designation underscores the potential benefits of MB-101 for patients contending with these aggressive forms of cancer. Dr. Manuel Litchman, President and CEO of Mustang Bio, expressed optimism regarding the broader indication for MB-101, viewing it as strong validation of the company’s scientific efforts to deliver innovative treatment options for individuals suffering from malignant glioma.

Moreover, encouraging preclinical findings highlight the potential efficacy of combining MB-101 with MB-108, an HSV-1 oncolytic virus, which aims to transform “cold” tumors into “hot” tumors to augment the effectiveness of CAR T-cell therapy. Data presented at the recent American Association for Cancer Research (AACR) Annual Meeting revealed that this combination was well tolerated by patients, yielding remarkable outcomes, including complete responses lasting up to 66 months.

With ongoing Phase 1 trials underway, Mustang Bio is poised to explore partnerships and funding opportunities that could advance their groundbreaking therapies and reshape the future landscape of cancer treatment.

Related news for (MBIO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.